- Home
- ZYXI
ZYXI
Zynex Inc.
as 12-20-2024 3:45pm EST
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | ENGLEWOOD |
| Market Cap: | 265.0M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 70.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -66.20 |
| 52 Week Low/High: | $7.15 - $13.77 | Next Earning Date: | 10-24-2024 |
| Revenue: | $193,665,000 | Revenue Growth: | 4.21% |
| Revenue Growth (this year): | 10.7% | Revenue Growth (next year): | 19.78% |
Stock Insider Trading Activity of Zynex Inc. (ZYXI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOORHEAD DANIEL J | ZYXI | CHIEF FINANCIAL OFFICER | Dec 2 '24 | Sell | $8.08 | 10,000 | $80,800.00 | 35,190 | |
| Sandgaard Thomas | ZYXI | PRESIDENT, CEO AND CHAIRMAN | Nov 14 '24 | Sell | $8.09 | 2,000 | $16,180.00 | 14,603,662 | |
| Sandgaard Thomas | ZYXI | PRESIDENT, CEO AND CHAIRMAN | Nov 7 '24 | Sell | $8.93 | 10,000 | $89,280.00 | 14,603,662 | |
| Sandgaard Thomas | ZYXI | PRESIDENT, CEO AND CHAIRMAN | Nov 4 '24 | Sell | $8.51 | 6,000 | $51,080.00 | 14,603,662 | |
| MOORHEAD DANIEL J | ZYXI | CHIEF FINANCIAL OFFICER | Nov 1 '24 | Sell | $8.59 | 10,000 | $85,900.00 | 35,190 | |
| Sandgaard Thomas | ZYXI | PRESIDENT, CEO AND CHAIRMAN | Oct 30 '24 | Sell | $8.79 | 6,000 | $52,740.00 | 14,603,662 |
Latest Zynex Inc. News
ZYXI Breaking Stock News: Dive into ZYXI Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
3 US Stocks Estimated To Be Trading Up To 32.9% Below Intrinsic Value
Simply Wall St.
4 days ago
An Intrinsic Calculation For Zynex, Inc. (NASDAQ:ZYXI) Suggests It's 22% Undervalued
PR Newswire
5 days ago
Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States
PR Newswire
10 days ago
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters
Zacks
13 days ago
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
Medical Device Network
16 days ago
Zynex completes clinical verification trial of pulse oximeter
PR Newswire
17 days ago
Zynex Announces Completion of Its Laser Pulse Oximetry Trial
PR Newswire
19 days ago
Zynex Announces Open Oximetry Project Membership
Compare ZYXI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZYXI Zynex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.